GoodRx Holdings, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
GDRX$3.65+4.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| (in thousands, except par values) | December 31, 2025 | December 31, 2024 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $261,820 | $448,346 |
| Accounts receivable, net | 235,746 | 145,934 |
| Prescription reimbursement assets | 98,331 | 22,944 |
| Prepaid expenses and other current assets | 47,205 | 42,031 |
| Total current assets | 643,102 | 659,255 |
| Property and equipment, net | 12,268 | 12,664 |
| Goodwill | 430,331 | 410,769 |
| Intangible assets, net | 64,082 | 52,102 |
| Capitalized software, net | 139,261 | 124,781 |
| Operating lease right-of-use assets, net | 28,808 | 27,794 |
| Deferred tax assets, net | 57,111 | 77,182 |
| Other assets | 29,095 | 23,520 |
| Total assets | $1,404,058 | $1,388,067 |
| Liabilities and stockholders' equity | ||
| Current liabilities | ||
| Accounts payable | $19,405 | $14,137 |
| Prescription reimbursement liabilities | 130,139 | 15,798 |
| Accrued expenses and other current liabilities | 86,705 | 83,332 |
| Current portion of debt | 5,000 | 5,000 |
| Operating lease liabilities, current | 4,753 | 5,636 |
| Total current liabilities | 246,002 | 123,903 |
| Debt, net | 483,264 | 486,711 |
| Operating lease liabilities, net of current portion | 49,789 | 46,040 |
| Other liabilities | 8,741 | 6,755 |
| Total liabilities | 787,796 | 663,409 |
| Commitments and contingencies (Note 13) | ||
| Stockholders' equity | ||
| Preferred stock, $0.0001 par value; 50,000 shares authorized and nil shares issued and outstanding at December 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.0001 par value; Class A: 2,000,000 shares authorized, 107,088 and 105,946 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively; and Class B: 1,000,000 shares authorized, 233,964 and 276,869 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 34 | 38 |
| Additional paid-in capital | 2,026,802 | 2,165,633 |
| Accumulated deficit | (1,410,574) | (1,441,013) |
| Total stockholders' equity | 616,262 | 724,658 |
| Total liabilities and stockholders' equity | $1,404,058 | $1,388,067 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.